U.S. patent application number 17/328239 was filed with the patent office on 2021-09-09 for native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3.
This patent application is currently assigned to TRELLIS BIOSCIENCE, LLC. The applicant listed for this patent is TRELLIS BIOSCIENCE, LLC. Invention is credited to Angeles ESTELLES, Mikhail GISHIZKY, Lawrence M. KAUVAR, Stefan RYSER.
Application Number | 20210277116 17/328239 |
Document ID | / |
Family ID | 1000005608509 |
Filed Date | 2021-09-09 |
United States Patent
Application |
20210277116 |
Kind Code |
A1 |
ESTELLES; Angeles ; et
al. |
September 9, 2021 |
NATIVE HUMAN ANTIBODIES FOR IMMUNE CHECKPOINT MODULATION TARGETS
TIM-3 AND B7-H3
Abstract
Novel monoclonal antibodies directed against immune checkpoint
modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating
cancer and immune system disorders.
Inventors: |
ESTELLES; Angeles; (Belmont,
CA) ; GISHIZKY; Mikhail; (Napa, CA) ; RYSER;
Stefan; (Menlo Park, CA) ; KAUVAR; Lawrence M.;
(San Francisco, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
TRELLIS BIOSCIENCE, LLC |
Redwood City |
CA |
US |
|
|
Assignee: |
TRELLIS BIOSCIENCE, LLC
Redwood City
CA
|
Family ID: |
1000005608509 |
Appl. No.: |
17/328239 |
Filed: |
May 24, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15861410 |
Jan 3, 2018 |
11046764 |
|
|
17328239 |
|
|
|
|
62441910 |
Jan 3, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/24 20130101;
C07K 2317/55 20130101; C07K 2317/92 20130101; C07K 2317/56
20130101; C07K 2317/565 20130101; C07K 16/2803 20130101; C07K
2317/31 20130101; C07K 16/30 20130101; A61P 35/00 20180101; C07K
2317/54 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C07K 16/30 20060101 C07K016/30; A61P 35/00 20060101
A61P035/00 |
Claims
1. An isolated nucleic acid or isolated nucleic acids that
separately or in combination encode a recombinantly produced
monoclonal antibody (mAb) or effective antigen-binding portion
thereof, which includes the CDR regions of TRL6042, TRL6061,
TRL10006, TRL6099, TRL6120 or TRL4542.
2. The nucleic acid or nucleic acids of claim 1 coupled to control
sequences for expression.
3. The nucleic acid or nucleic acids of claim 2 contained in a
vector.
4. Host cells containing a vector of claim 3.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional of U.S. patent application
Ser. No. 15/861,410, filed Jan. 3, 2018, which claims priority to
U.S. Provisional Application No. 62/441,910, filed Jan. 3, 2017,
each of which is incorporated herein by reference in its
entirety.
SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE
[0002] The content of the following submission on ASCII text file
is incorporated herein by reference in its entirety: a computer
readable form (CRF) of the Sequence Listing (file name:
12774-136US2_SeqList.txt, date recorded: May 21, 2021, size: 11
kilobytes).
TECHNICAL FIELD
[0003] The present invention relates to antibody molecules that can
directly bind immune checkpoint modulator (ICM) proteins and thus
regulate the function of an individual's immune system. More
specifically, it relates to human antibodies capable of promoting
elimination of tumor cells by T lymphocytes (T cells), Natural
Killer cells (NK cells) and myeloid cells by either reducing
inhibitory signals or augmenting stimulatory signals emanating from
two ICM proteins, T cell immunoglobulin and mucin domain 3 protein
(TIM-3, CD366), and B7-H3 (CD276). In addition, B7-H3 has been
shown to be overexpressed in many cancers, hence direct targeting
of B7-H3 on the tumor cell can be used to eliminate the cancer.
Further, the invention relates to pharmaceutical use of such agents
as well as to methods of manufacturing such agents using
transfected cell lines.
BACKGROUND ART
[0004] Over the past 20 years, discovery of antibody therapeutics
for cancer has focused on proteins associated with tumor cells
(also known as tumor-associated antigens -TAAs-). Several such
anti-tumor antibody drugs have been commercialized, including those
targeting VEGF, Her2, EGFR, and CD20. The need for an exogenous
source of these antibodies arises from the high variability in the
natural immune response to tumor associated antigens. This
variability is due in part to tumor secretion of immunosuppressive
factors. Over the past 5 years, a new class of cancer therapeutics
has been developed clinically that act by stimulating the immune
system, thereby improving the body's natural ability to fight
cancer. This class of therapeutics is known as immune checkpoint
modulators (ICM). So far, all of the drugs in this class have
themselves been antibodies, including the approved drugs Yervoy.TM.
(ipilimumab), Opdivo.TM. (nivolumab) and Keytruda.TM.
(pembrolizumab) whose respective targets are CTLA-4, PD-1 and
PD-L1. These ICM antibodies work by temporarily lifting a brake on
the immune system thereby counteracting tumor induced immune
suppression. The ICM drugs have proven to be particularly effective
in treating melanoma, which frequently secretes immune suppressing
factors.
[0005] Increased efficacy from combinations of these first
generation ICM antibodies has been observed clinically, but
accompanied by increased toxicity that resembles autoimmune
disease. Further improvement thus depends on identifying
combinations of agents that boost anti-tumor immunity while
minimizing the adverse consequences of immune system stimulation.
Native human antibodies with ICM activity are of particular
interest in this regard, as they have been pre-selected naturally
to be well tolerated. Such native antibodies may preferentially
bind to particular ICM targets, or to particular epitopes on those
targets. More than 20 potential ICM targets have been described in
the scientific literature. Of particular interest for the present
invention are antibody molecules that bind ICM proteins TIM-3 and
B7-H3.
[0006] Alternatively, B7-H3 is an appropriate TAA for antibody
targeted treatment since its expression is mainly restricted to the
tumor, minimizing the risk of cytotoxicity in normal tissues. Of
interest are B7-H3 antibodies that are able to mediate
antibody-dependent cell-mediated cytotoxicity (ADCC). Also of
interest are antibodies capable of being internalized in the cancer
cells, making them candidates for Antibody Drug Conjugates (ADC)
that can carry toxins or radioligands into the cell. Native human
antibodies with anti-B7-H3 activity of either type are of
particular value for minimizing off-target reactivity and rejection
as a foreign protein.
[0007] U.S. Pat. No. 7,470,428 discloses the full length protein
TIM-3 sequence ("Compositions and methods related to TIM-3, a Th1
specific cell surface molecule"). U.S. 2016/0257758 ("Antibody
therapeutics that bind TIM3"); U.S. Pat. No. 8,552,156 ("Anti-TIM-3
Antibody"); U.S. 2015/218274 ("Antibody molecules to TIM-3 and uses
thereof"); U.S. 2016/0257749 ("Anti-TIM3 antibodies and methods of
use") and U.S. 2015/0086574 disclose "Antibodies binding to the
Extracellular Domain (ECD) of TIM3". The antibodies disclosed
below, derived from the natural human immune repertoire, and
produced recombinantly are distinct compositions from these
antibodies.
[0008] U.S. Pat. 2002/0198143 discloses the full length protein
B7-H3 sequence ("B7-Like Polynucleotides, Polypeptides and
Antibodies"). U.S. 2013/0078234 ("Anti B7-H3 Antibody") and U.S.
Pat. No. 8,802,091 ("Antibodies reactive with B7-H3 and uses
thereof") disclose Antibodies binding to the Extracellular Domain
(ECD) of B7-H3. The antibodies disclosed below, derived from the
natural human immune repertoire, and produced recombinantly are
distinct compositions from these antibodies.
DISCLOSURE OF THE INVENTION
[0009] To generate therapeutic antibodies against the broad class
of candidate ICM targets, we have used our previously described
CellSpot technology for identifying rare antibodies (defined by
specificity and affinity) within the memory B-cell compartment of
the human immune system. Native human antibodies against several
ICM targets have been recovered by this means. Surprisingly these
antibodies have been cloned from healthy blood donors with no known
cancer. In other words, the pharmacological approach represented by
administration of ICM antibodies appears to have a natural
counterpart, consistent with the long standing immune surveillance
concept that in healthy individuals incipient tumors are eliminated
by the immune system. The low frequency of memory B cells making
high affinity antibodies to ICM targets further suggests that the
natural ICM mechanism is transient, leaving a footprint in the
memory B cell repertoire without leading to long term autoimmune
disease. Here we describe antibody molecules that selectively bind
to either TIM-3 or B7-H3 with high affinity and specificity. These
antibody molecules can be used (alone or in combination with other
agents or therapeutic modalities) to treat, prevent and/or diagnose
cancer, immune disorders, infectious disease, Crohn's disease,
sepsis and other immune system related health diseases.
[0010] TIM-3 is a transmembrane glycoprotein that is expressed on T
cells (Monney, L., et al., Nature (2002) 415:536-541) as well as
phagocytic cells such as macrophages and dendritic cells (Chiba,
S., et al., Nat. Immunol. (2012) 13:832-842). TIM-3 is believed to
be a negative regulator of T cell responses. For example, binding
of TIM-3 to its putative ligand, galectin-9, on Th1 cells, results
in Th1 cell death. Further, blockade of TIM-3 increases IFN-7
secreting T cells (Zhu, C., et al., Nat. Immunol. (2005)
6:1245-1252). Additionally, co-blockade of TIM-3 and another of its
putative ligands, CEACAM1, leads to enhancement of anti-tumor
immune responses with improved elimination of tumors in mouse
colorectal cancer models (Huang. Y. H., et al., Nature (2015)
517:386-390). Microarray analysis of hematopoietic stem cells from
acute myeloid leukemia (AML) patients and normal hematopoietic stem
cells revealed that TIM-3 is expressed on AML stem cells. This
analysis suggests the possible involvement of TIM-3 in
hematological malignancy (Majeti, R., et al., Proc. Natl. Acad.
Sci. (2009) 106:3396-3401).
[0011] B7-H3 is a transmembrane glycoprotein belonging to the
"B7-CD28" immunoregulatory superfamily with two
immunoglobulin-V-like and two immunoglobulin-C-like domains (e.g.,
IgV-IgC; Steinberger, P., et al., J Immunol. (2004) 172:2352-9).
Other members of this family include inducible co-stimulator ligand
(ICOS-L), the programmed death-1 ligand (PD-L1) and, the programmed
death-2 ligand (PD-L2)(Collins M., et al., Genome Biol. (2005)
6:223), B7-H3 protein expression is tightly regulated in healthy
individuals and is not expressed on resting B or T cells,
monocytes, or dendritic cells. However, B7-H3 is induced on
dendritic cells by IFN-7 and on monocytes by GM-CSF (Sharpe, A. H.
and Freeman, G. J. Nat Rev Immunol (2002) 2:116-26) and is believed
to inhibit Th1, Th2, or Th17 cells in vivo (Prasad, D. V., et al.,
J Immunol (2004) 173:2500-2506 and Yi, K. H. and Chen, L. Immunol
Rev (2009) 229:145-151). Increased expression of B7-H3 on tumor
cells is associated with increased severity of disease and poorer
clinical outcomes (Zang, X., et al., Mod. Pathol. (2010)
23:1104-1112), suggesting that B7-H3 is exploited by tumors as an
immune evasion pathway (Hofmeyer. K. A. et al., Proc. Natl. Acad.
Sci. USA. (2008) 105:10277-8; Picarda, E. et al., Clin Cancer Res
(2016) 22:3425-31). Furthermore, B7-H3 has been shown to be
upregulated in many types of cancers (while no presence was found
in surrounding healthy tissues) such as: breast cancer (Arigami,
T., et al., Ann. Surg. (2010) 252:1044-1051); neuroblastoma
(Castriconi. R., et al., Proc. Natl. Acad. Sci. USA. (2004)
101:12640-12645; Kramer, K., et al., J. Neurooncol. (2010)
97:409-418); melanoma (Wang, J., et al., J. Invest Dermatol. (2013)
133:2050-2058); gastric carcinoma (Wu, C. P., et al., World J.
Gestroenterol. (2006) 12:457-459); pancreatic cancer (Yamato, I.,
et el., Br. J. Cancer. (2009) 101:1709-1716) and ovarian carcinoma
(Zang, supra 2010). Direct target of B7-H3 alone or conjugated with
a toxin or radioligand can be of interest in this regard.
Modes of Carrying Out the Invention
[0012] Human antibodies such as those disclosed here are
particularly favorable from both an efficacy perspective (having
been cloned from healthy donors) and a safety perspective (reduced
chance of off-target reactivity that would create toxicity). The
frequency of human antibodies to a particular target in the natural
human repertoire is typically orders of magnitude lower than in the
repertoire of immunized mice. Accordingly, a high throughput
technology capable of surveying millions of individual antibody
producing human B lymphocytes is needed. Since human B cells have a
very limited lifetime ex vivo (under 10 days), the technology must
also operate within that time window.
[0013] To accomplish the survey and recovery of rare favorable
cells, we used the previously described CellSpot.TM. technology
(U.S. Pat. Nos. 7,413,868 and 7,939,344, incorporated herein by
reference). This assay method effectively shrinks an ELLSA
equivalent assay down to a virtual well of nearly single cell
dimensions by capturing secreted IgG from a single cell as a
footprint in the vicinity of the cell. In that way, 5 million B
cells can be readily analyzed. Further, by use of microscopic
multiplexing reagents (combinatorially colored fluorescent latex
microspheres, cf U.S. Pat. No. 6,642,062, incorporated herein by
reference), each clone's secreted antibody footprint can be
characterized in detail for specificity and/or affinity using
multiple biochemical probes. The fidelity of the quantitative assay
is sufficient to enable rescue of extremely rare favorable cells
from the survey population. The cloned antibody encoding genes
expressed in an exogenous cell typically show a phenotype
consistent with the original identifying assay.
[0014] The fully human antibodies of the invention are distinct
from those found in nature, as they are prepared recombinantly. For
complete antibodies, this includes constructing nucleic acids that
encode a generic form of the constant region of heavy and/or light
chain and further encode heterologous variable regions that are
representative of human antibodies. Moreover, because the B cells
are cultured prior to assay, mutations may arise during this ex
vivo period.
[0015] As used herein, the term "antibody" includes immunoreactive
fragments of traditional antibodies and their various fragmented
forms that still retain immunospecificity such as Fab,
F(ab').sub.2, F.sub.v fragments, single-chain antibodies in which
the variable regions of heavy and light chain are directly bound
without some or all of the constant regions. Also included are
bispecific antibodies which contain a heavy and light chain pair
derived from one antibody source and a heavy and light chain pair
derived from a different antibody source. Similarly, since light
chains are often interchangeable without destroying specificity,
antibodies composed of a heavy chain variable region that
determines the specificity of the antibody combined with a
heterologous light chain variable region are included within the
scope of the invention. Chimeric antibodies with constant and
variable regions derived, for example, from different species are
also included.
[0016] For the variable regions of mAbs, as is well known, the
critical amino acid sequences are the CDR sequences arranged on a
framework which framework can vary without necessarily affecting
specificity or decreasing affinity to an unacceptable level.
Definition of these CDR regions is accomplished by art-known
methods. Specifically, the most commonly used method for
identifying the relevant CDR regions is that of Kabat as disclosed
in Wu. T. T., et al., J. Exp. Med. (1970) 132:211-250 and in the
book Kabat. E. A., et al. (1983) Sequence of Proteins of
Immunological Interest, Bethesda National Institute of Health, 323
pages. Another similar and commonly employed method is that of
Chothia, published in Chothia, C., et al., J. Mol. Biol. (1987)
196:901-917 and in Chothia, C., et al., Nature (1989) 342:877-883.
An additional modification has been suggested by Abhinandan, K. R.,
et al., Mol. Immnunol. (2008) 45:3832-3839. The present invention
includes the CDR regions as defined by any of these systems or
other recognized systems known in the art.
[0017] The specificities of the binding of the mAbs of the
invention are defined, as noted, by the CDR regions mostly those of
the heavy chain, but complemented by those of the light chain as
well (the light chains being somewhat interchangeable). Therefore,
the mAbs of the invention may contain the three CDR regions of a
heavy chain and optionally the three CDR's of a light chain that
matches it. Because binding affinity is also determined by the
manner in which the CDR's are arranged on a framework, the mAbs of
the invention may contain complete variable regions of the heavy
chain containing the three relevant CDR's as well as, optionally,
the complete light chain variable region comprising the three CDR's
associated with the light chain complementing the heavy chain in
question. This is true with respect to the mAbs that are
immunospecific for a single epitope as well as for bispecific
antibodies or binding moieties that are able to bind two separate
epitopes.
[0018] Bispecific binding moieties may be formed by covalently
linking two different binding moieties with different
specificities. Multiple technologies now exist for making a single
antibody-like molecule that incorporates antigen specificity
domains from two separate antibodies (bi-specific antibody).
Suitable technologies have been described by MacroGenics
(Rockville, Md.). Micromet (Bethesda, Md.) and Merrimac (Cambridge,
Mass.). (See, e.g., Orcutt, K. D., et al., Protein Eng. Des. Sel.
(2010) 23:221-228; Fitzgerald. J., et al., MAbs. (2011) 1:3;
Baeuerle, P. A., et al., Cancer Res. (2009) 69:4941-4944). For
example, the CDR regions of the heavy and optionally light chain
derived from one monospecific mAb may be coupled through any
suitable linking means to peptides comprising the CDR regions of
the heavy chain sequence and optionally light chain of a second
mAb. If the linkage is through an amino acid sequence, the
bispecific binding moieties can be produced recombinantly and the
nucleic acid encoding the entire bispecific entity expressed
recombinantly. As was the case for the binding moieties with a
single specificity, the invention also includes the possibility of
binding moieties that bind to one or both of the same epitopes as
the bispecific antibody or binding entity/binding moiety that
actually contains the CDR regions. The invention further includes
bispecific constructs which comprise the complete heavy and light
chain sequences or the complete heavy chain sequence and at least
the CDR's of the light chains or the CDR's of the heavy chains and
the complete sequence of the light chains.
[0019] The mAbs that are the subject of the present invention are
not isolated from human blood or plasma, but rather are
recombinantly produced. In brief, human blood cells that secrete
antibodies are assessed to identify those cells that secrete mAbs
of appropriate specificity and affinity. The RNA or DNA encoding
these antibodies is extracted from the cells thus identified and
the variable regions cloned. The resulting DNA encoding the heavy
and light chain variable regions is coupled to DNA encoding generic
constant regions and the resulting recombinant DNA encoding the
complete antibody in each case is provided with control sequences
to effect expression and secretion of the recombinant mAbs.
Alternatively, the variable regions may be directly employed to
encode, for example, single-chain forms of the mAbs. Suitable
control sequences and secretion signal encoding sequences are well
known in the art as are methods for recombinant production of
encoding nucleic acids.
[0020] The mAbs of the invention are thus recombinantly produced
using known techniques. The invention also includes nucleic acid
molecules comprising nucleotide sequence encoding them, as well as
vectors or expression systems that comprise these nucleotide
sequences, cells containing expression systems or vectors for
expression of these nucleotide sequences and methods to produce the
binding moieties by culturing these cells and recovering the
binding moieties produced. Any type of cell typically used in
recombinant methods can be employed including prokaryotes, yeast,
mammalian cells, insect cells and plant cells. Also included are
human cells (e.g., muscle cells or lymphocytes) transformed with
one or more recombinant molecules that encodes the novel
antibodies.
[0021] Typically, expression systems for the mAbs of the invention
include one or more nucleic acids encoding said at least the
variable regions coupled to control sequences for expression. In
many embodiments, the control sequences are heterologous to the
nucleic acid encoding the protein. The invention is also directed
to nucleic acids encoding the bispecific moieties and to
recombinant methods for their production, as described above.
[0022] Thus, typically the nucleic acids encoding the mAbs or
antigen-binding portions thereof are comprised in vectors that
include expression systems for said encoding nucleic acids, which
vectors are functional in transforming recombinant host cells for
the production of the desired mAb or antigen-binding portion.
[0023] The invention is also directed to pharmaceutical and
veterinary compositions which comprise as active ingredients the
antibodies of the invention. The compositions contain suitable
physiologically compatible excipients such as buffers and other
simple excipients. The compositions may include additional active
ingredients as well, in particular anti-tumor chemotherapeutic
agents. The binding moieties of the invention may also be used in
diagnosis.
[0024] The following examples are offered to illustrate but not to
limit the invention.
EXAMPLE 1
[0025] Human blood from anonymized donors from the Stanford Blood
Center, obtained under informed consent, were screened for six ICM
targets, including TIM-3 and B7-H3. The cells were subjected to the
CellSpot.TM. assay to determine their ability to bind the antigens.
The CellSpot.TM. assay is described in U.S. Pat. Nos. 7,413,868 and
7,939,344. After isolating Human peripheral blood mononuclear cells
(PBMC's), they were stimulated with cytokines and mitogens to
initiate a brief period of memory B cell proliferation,
differentiation and antibody secretion (lasting 5 days) and plated
for subjection to the assay. The encoding nucleic acids for the
variable regions of positive antibodies were extracted and used to
produce the antibodies recombinantly by cloning the DNA in
expression vectors containing a signal peptide as well as the
constant region for the heavy and light chains.
EXAMPLE 2
[0026] The TIM-3 antibody molecules of the present invention were
cloned following a survey of 22 blood donors for binding to 6
different ICM antigens, including the extracellular domain (ECD) of
TIM-3. Anti-TIM-3 antibodies were detected in 15 of the donors at
different frequencies (Table 1 and 2). BSA was used as a
counterscreen to eliminate polyreactive antibodies. Four mAbs were
cloned.
TABLE-US-00001 TABLE 1 Frequencies of anti-TIM-3 CellSpot .TM.'s in
all doors tested Donor TIM-3 # CellSpot .TM.'s/100K Memory Cells
SBC207 0.3 SBC210 0.2 SBC222 0 SBC223 2.7 SBC224 0 SBC230 0.6
SBC235 1.2 SBC236 0.4 SBC238 2.8 SBC240 1.6 SBC241 0 SBC243 0
SBC246 0.3 SBC248 0.6 SBC251 0 SBC252 0 SBC254 0.1 SBC255 0.4
SBC256 0 SBC258 1.4 INF 6.11 0.6 INF 4.2 1.9
TABLE-US-00002 TABLE 2 Donors for Trellis Anti-TIM-3 antibodies
TIM-3 TRLmAb Donor # 6042 236 6061 207 6099 254 6120 238
[0027] Purified mAbs were tested in adsorption ELISA using TIM-3
ECD, generated by Trellis in mammalian cells. Serial dilutions
allowed calculating an estimate of the binding affinities (values
listed in Table 3 are expressed as nM). TRL6061 and 6099 are of
particular interest based on its sub-nM affinity to the target. A
diverse set of germline variable regions was found in this group of
mAbs as seen in Table 4.
TABLE-US-00003 TABLE 3 Affinities for Trellis Anti-TIM-3 TIM-3
TRLmAb Affinity (nM) 6042 5 6061 0.005 6099 0.011 6120 28
TABLE-US-00004 TABLE 4 Germlines for Trellis Anti-TIM-3 antibodies
TIM-3 TRLmAb VH germline VL germline 6042 IGHV5-51*01 IGKV1-9*01
6061 IGHV3-33*01 IGLV3-10*01 6099 IGHV3-38*01 IGLV1-44*01 6120
IGHV3-33*01 IGLV3-10*01
[0028] Sequences of Trellis anti TIM-3 VH and VL in amino
acids:
TABLE-US-00005 TRL6042 VH (SEQ ID NO: 1)
qvglvesgaevkkpgeslkiscegsgykftsywigwvrqmpgrgpewmgli
ypsdsdtryspsfrgvtisvdktistaylqwsslktsdtaiyycarlllat
ectsdscfgdafdiwgqgtmvtvss TRL6042 VL (kappa) (SEQ. ID NO: 2)
divltqsptflsasvgdrvtitcrasqgissylawyqqkpgkapklllyaa
stlgsgvpsrfsgsrsgteftltisslqpedfasyycqqfhnypftfgggt kveikr TRL6061
VH (SEQ ID NO: 3)
qvqlvesgggvvqpgrslrlscaasgfmfstsamhwvrqtpgkglewlavi
whdgsekyyadsvkgrfsisrdnyrdtlylqmnnlrvedtaiyycrggdvy eiwgqgtmvavss
TRL6061 VL (lambda) (SEQ ID NO: 4)
ddimltqppsvsvspgqtaritcsgdavakryvywyqqksgqapvlvmyed
nkrpsgiperfsgsssgtkatltitgalvedeadyycystdssgnlgafgg gskltvl TRL6099
VH (SEQ ID NO: 5)
qvglvesgaevkkpgasvkvsckafnytftsygiswvrqtpehglewmgwi
tnsnsnsaqkfqgrvsmttdtststaymqlrslssddtavyycariyidyn
nygldvwgqgttvtvss TRL6099 VL (lambda) (SEQ ID NO: 6)
divltqspsasgtpgqrviiscsgsssniggntvnwyqqlpgtapklliys
ndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslsgpafg ggtkltvlg
TRL6120 VH (SEQ ID NO: 7)
qvqlvesgggvvqpgrslrlscvasgfifrtyamhwvrqapgkglewvavi
wpdgseryysdstkgrftvsrdnskntlflqmnslrvddtamyycfargys
dsdyadhwgrgtrvtvss TRL6120 VL (lambda) (SEQ ID NO: 8)
divmtqspsvsvspgqtaritcsgdalstkfaywyqqksgqapvlviyedn
krpsgiperfsgsgsgtmatlgvseaqvedeadyycfssdssgnlfmfggg tkltvl
EXAMPLE 3
[0029] The B7-H3 antibody of the present invention was cloned
following a survey of 14 blood donors for binding to 6 different
ICM antigens, including the ECD of B7-H3. Anti-B7-H3 antibodies
were detected in only 3 of the donors at low frequencies (Tables 5
and 6), suggesting that these antibodies are rarer than anti-TIM-3
antibodies in healthy donors (Table 1). BSA was used as a
counterscreen to eliminate polyreactive antibodies. One antibody
was cloned.
TABLE-US-00006 TABLE 5 Frequencies of anti-B7-H3 CellSpots in all
doors tested Donor B7-H3 # CellSpot .TM.'s/100K Memory Cells SBC224
0 SBC227 0 SBC232 0 SBC234 0.8 SBC235 0.3 SBC237 0 SBC238 0 SBC238
0.5 SBC243 0 SBC247 0 SBC254 0 SBC255 0 AC1628 0 AC1681 0
TABLE-US-00007 TABLE 6 Donors for Trellis Anti-B7-H3 antibody TIM-3
TRLmAb Donor # 4542 254
[0030] Purified mAb was tested in adsorption ELISA using B7-H3 ECD,
generated by Trellis in mammalian cells. Serial dilutions allowed
calculating an estimate of the binding affinities (value listed in
Table 7 is expressed as nM). In Table 8 is shown the germlines for
the heavy and light chain variable regions.
TABLE-US-00008 TABLE 7 Affinities for Trellis Anti-B7-H3 antibody
B7-H3 TRLmAb Donor # 4542 5
TABLE-US-00009 TABLE 8 Germlines for Trellis Anti-B7-H3 antibody
B7-H3 TRLmAb VH germline VL germline 4542 IGHV3-15*01
IGKV4-1*01
[0031] Sequences of Trellis Anti-B7-H3 VH and VL in amino
acids:
TABLE-US-00010 TRL4542 VH (SEQ ID NO: 9)
qvqlvesggdlvqpgeslrlscaasgfifsdawmvwvrqapgkglewvgri
ktngdggttdltepvkgrftisrddsknmvylqmnnlrtedtaiyycttap gfwgqgtlvtvss
TRL4542 VL (kappa) (SEQ ID NO: 10)
diemtqspdslavslgeratincksshnllyksnnknylawsqqkpgqppr
lliywastrdsgvpdrfsgsgsgtdftltisslqaedvayychqyygtkwt fgqgtrveikr
Sequence CWU 1
1
101128PRTHomo sapiens 1Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val
Lys Lys Pro Gly Glu1 5 10 15Ser Leu Lys Ile Ser Cys Glu Gly Ser Gly
Tyr Lys Phe Thr Ser Tyr 20 25 30Trp Ile Gly Trp Val Arg Gln Met Pro
Gly Arg Gly Pro Glu Trp Met 35 40 45Gly Leu Ile Tyr Pro Ser Asp Ser
Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60Arg Gly Gln Val Thr Ile Ser
Val Asp Lys Thr Ile Ser Thr Ala Tyr65 70 75 80Leu Gln Trp Ser Ser
Leu Lys Thr Ser Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Arg Leu Leu
Leu Ala Thr Glu Cys Thr Ser Asp Ser Cys Phe Gly 100 105 110Asp Ala
Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120
1252108PRTHomo sapiens 2Asp Ile Val Leu Thr Gln Ser Pro Thr Phe Leu
Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
Gln Gly Ile Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Leu 35 40 45Tyr Ala Ala Ser Thr Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Glu Phe
Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Ser
Tyr Tyr Cys Gln Gln Phe His Asn Tyr Pro Phe 85 90 95Thr Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys Arg 100 1053115PRTHomo sapiens 3Gln Val
Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Met Phe Ser Thr Ser 20 25
30Ala Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45Ala Val Ile Trp His Asp Gly Ser Glu Lys Tyr Tyr Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Tyr Arg Asp Thr
Leu Tyr65 70 75 80Leu Gln Met Asn Asn Leu Arg Val Glu Asp Thr Ala
Ile Tyr Tyr Cys 85 90 95Arg Gly Gly Asp Val Tyr Glu Ile Trp Gly Gln
Gly Thr Met Val Ala 100 105 110Val Ser Ser 1154109PRTHomo sapiens
4Asp Asp Ile Met Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly1 5
10 15Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Val Ala Lys Arg
Tyr 20 25 30Val Tyr Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu
Val Met 35 40 45Tyr Glu Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg
Phe Ser Gly 50 55 60Ser Ser Ser Gly Thr Lys Ala Thr Leu Thr Ile Thr
Gly Ala Leu Val65 70 75 80Glu Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser
Thr Asp Ser Ser Gly Asn 85 90 95Leu Gly Ala Phe Gly Gly Gly Ser Lys
Leu Thr Val Leu 100 1055119PRTHomo sapiens 5Gln Val Gln Leu Val Glu
Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser
Cys Lys Ala Phe Asn Tyr Thr Phe Thr Ser Tyr 20 25 30Gly Ile Ser Trp
Val Arg Gln Thr Pro Glu His Gly Leu Glu Trp Met 35 40 45Gly Trp Ile
Thr Asn Ser Asn Ser Asn Ser Ala Gln Lys Phe Gln Gly 50 55 60Arg Val
Ser Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Gln65 70 75
80Leu Arg Ser Leu Ser Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95Ile Tyr Ile Asp Tyr Asn Asn Tyr Gly Leu Asp Val Trp Gly Gln
Gly 100 105 110Thr Thr Val Thr Val Ser Ser 1156111PRTHomo sapiens
6Asp Ile Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln1 5
10 15Arg Val Ile Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly
Asn 20 25 30Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys
Leu Leu 35 40 45Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp
Arg Phe Ser 50 55 60Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile
Ser Gly Leu Gln65 70 75 80Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala
Ala Trp Asp Asp Ser Leu 85 90 95Ser Gly Pro Ala Phe Gly Gly Gly Thr
Lys Leu Thr Val Leu Gly 100 105 1107120PRTHomo sapiens 7Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu
Arg Leu Ser Cys Val Ala Ser Gly Phe Ile Phe Arg Thr Tyr 20 25 30Ala
Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Val Ile Trp Pro Asp Gly Ser Glu Arg Tyr Tyr Ser Asp Ser Thr
50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu
Phe65 70 75 80Leu Gln Met Asn Ser Leu Arg Val Asp Asp Thr Ala Met
Tyr Tyr Cys 85 90 95Phe Ala Arg Gly Tyr Ser Asp Ser Asp Tyr Ala Asp
His Trp Gly Arg 100 105 110Gly Thr Arg Val Thr Val Ser Ser 115
1208108PRTHomo sapiens 8Asp Ile Val Met Thr Gln Ser Pro Ser Val Ser
Val Ser Pro Gly Gln1 5 10 15Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala
Leu Ser Thr Lys Phe Ala 20 25 30Tyr Trp Tyr Gln Gln Lys Ser Gly Gln
Ala Pro Val Leu Val Ile Tyr 35 40 45Glu Asp Asn Lys Arg Pro Ser Gly
Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60Gly Ser Gly Thr Met Ala Thr
Leu Ser Val Ser Glu Ala Gln Val Glu65 70 75 80Asp Glu Ala Asp Tyr
Tyr Cys Phe Ser Ser Asp Ser Ser Gly Asn Leu 85 90 95Phe Met Phe Gly
Gly Gly Thr Lys Leu Thr Val Leu 100 1059115PRTHomo sapiens 9Gln Val
Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asp Ala 20 25
30Trp Met Val Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Gly Arg Ile Lys Thr Asn Gly Asp Gly Gly Thr Thr Asp Leu Thr
Glu 50 55 60Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys
Asn Met65 70 75 80Val Tyr Leu Gln Met Asn Asn Leu Arg Thr Glu Asp
Thr Ala Ile Tyr 85 90 95Tyr Cys Thr Thr Ala Pro Gly Phe Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser 11510114PRTHomo sapiens
10Asp Ile Glu Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1
5 10 15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser His Asn Leu Leu Tyr
Lys 20 25 30Ser Asn Asn Lys Asn Tyr Leu Ala Trp Ser Gln Gln Lys Pro
Gly Gln 35 40 45Pro Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Asp
Ser Gly Val 50 55 60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr65 70 75 80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala
Val Tyr Tyr Cys His Gln 85 90 95Tyr Tyr Gly Thr Lys Trp Thr Phe Gly
Gln Gly Thr Arg Val Glu Ile 100 105 110Lys Arg
* * * * *